[{"id":"4aa1090c-9d65-40fd-9d0e-612440e8fda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341570","created_at":"2022-04-22T13:53:36.251Z","updated_at":"2024-07-02T16:36:11.592Z","phase":"Phase 1","brief_title":"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668","source_id_and_acronym":"NCT05341570","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-21668"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2022-04-22"}]